GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Claritev Corp (NYSE:CTEV) » Definitions » Debt-to-EBITDA

CTEV (Claritev) Debt-to-EBITDA : 10.22 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Claritev Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Claritev's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $19.3 Mil. Claritev's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $4,612.5 Mil. Claritev's annualized EBITDA for the quarter that ended in Mar. 2025 was $453.2 Mil. Claritev's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2025 was 10.22.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Claritev's Debt-to-EBITDA or its related term are showing as below:

CTEV' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -8.85   Med: 6.96   Max: 30.21
Current: -8.85

During the past 7 years, the highest Debt-to-EBITDA Ratio of Claritev was 30.21. The lowest was -8.85. And the median was 6.96.

CTEV's Debt-to-EBITDA is ranked worse than
100% of 457 companies
in the Healthcare Providers & Services industry
Industry Median: 2.55 vs CTEV: -8.85

Claritev Debt-to-EBITDA Historical Data

The historical data trend for Claritev's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Claritev Debt-to-EBITDA Chart

Claritev Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA
Get a 7-Day Free Trial 23.97 6.04 30.21 7.01 -4.51

Claritev Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.06 -2.74 -4.99 231.88 10.22

Competitive Comparison of Claritev's Debt-to-EBITDA

For the Health Information Services subindustry, Claritev's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Claritev's Debt-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Claritev's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Claritev's Debt-to-EBITDA falls into.


;
;

Claritev Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Claritev's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(17.635 + 4523.582) / -1007.904
=-4.51

Claritev's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(19.297 + 4612.527) / 453.228
=10.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2025) EBITDA data.


Claritev  (NYSE:CTEV) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Claritev Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Claritev's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Claritev Business Description

Traded in Other Exchanges
N/A
Address
7900 Tysons One Place, Suite 400, McLean, VA, USA, 22102
Claritev Corp is a healthcare technology, data, and insights company focused on improving transparency, affordability, and quality. The company provides tech-enabled solutions and services to interpret clients' needs and customize solutions that combine its payment integrity, network-based, and analytics-based services. The Company's focus is being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the U.S. healthcare industry.
Executives
Michael Kim officer: See Remarks POLARIS PARENT CORP, 115 FIFTH AVENUE, NEW YORK NY 10003
Anthony Jr Colaluca director MULTIPLAN CORPORATION, 115 FIFTH AVENUE, NEW YORK NY 10003
John Michael Prince director 115 FIFTH AVE., NEW YORK NY 10003
Nutter Carol officer: SVP, Chief People Officer 115 FIFTH AVE., NEW YORK NY 10003
Mark Tabak director, officer: Chief Executive Officer 115 FIFTH AVENUE, NEW YORK NY 10003
Michael K. Attal director 425 PARK AVENUE, 30TH FLOOR, NEW YORK NY 10022
James M Head officer: EVP & Chief Financial Officer 3001 COLORADO BLVD, DENTON TX 76210
Julie D Klapstein director 1239 FRUIT COVE ROAD NORTH, JACKSONVILLE FL 32259
C Martin Harris director
H&f Corporate Investors Viii, Ltd. 10 percent owner 415 MISSION STREET, SUITE 5700, SAN FRANCISCO CA 94105
Music Investments Gp, Llc 10 percent owner C/O HELLMAN & FRIEDMAN, ONE MARTIME PLAZA, 12TH FLOOR, SAN FRANCISCO CA 94111
Music Investments, L.p. 10 percent owner C/O HELLMAN & FRIEDMAN, ONE MARTIME PLAZA, 12TH FLOOR, SAN FRANCISCO CA 94111
Glenn R August director C/O OHA - 1114 AVENUE OF THE AMERICAS, 27TH FLOOR, NEW YORK NY 10036
Paul Galant officer: President, New Markets 88 WEST PLUMERIA DRIVE, SAN JOSE CA 95134
Michael Stuart Klein director, 10 percent owner, officer: Chief Executive Officer C/O DAVIS POLK & WARDWELL, 450 LEXINGTON AVENUE, NEW YORK NY 10017